jan. ind clearance for the multinational clinical trial of hg004 (hg00402) to treat inherited retinal diseases (irds) by the u.s. fdajan. huidagene dosed first subject in the hg004 iit (hg00401) clinical trial for rpe65 mutation-associated irdmar. hg004 granted orphan drug designation by the u.s. fdaapr. huidagene received ind approval of the first china multi-regional, multi-national master protocol of hg004 (hg00402) by china nmpaapr. discovery of glycosylase-based guanine base editor (ggbe)may. us patent covering crispr-cas12 dna editing tools granted by usptomay. discovery of glycosylase-based guanine base editor (ggbe)aug. fda granted rare pediatric disease designation (rpdd) to hg004sep. first patient dosed of the world’s first novel crispr/cas13 rna-editing therapy,hg202oct. fda granted rpdd to hg204 for the treatment of mecp2 duplication syndrome